Polar Asset Management Partners’s ADMA Biologics ADMA Stock Holding History

Polar Asset Management Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-600,000	Closed	-$1.19M	–	1395
2022 Q2	$1.19M	Sell	600,000 -687,600	-53%	-$1.35M	0.01%	743
2022 Q1	$2.36M	Hold	1,287,600	–	–	0.03%	604
2021 Q4	$1.82M	Buy	+1,287,600	New	+$1.69M	0.02%	627

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Polar Asset Management Partners's ADMA Position: Q3 2022 in Review

Polar Asset Management Partners sold out of ADMA Biologics (ADMA) in Q3 2022, closing a stake of 600,000 shares — an estimated $1.19M sold.

Polar Asset Management Partners first reported a position in ADMA in Q4 2021 and held it in 3 quarters. The position peaked at $2.36M in Q1 2022. 130 funds tracked by Wall St. Rank hold ADMA as of Q3 2022.

Polar Asset Management Partners reported no remaining ADMA Biologics position as of Q3 2022 after selling out during the quarter.
Polar Asset Management Partners sold 600,000 ADMA Biologics shares in Q3 2022, an estimated $1.19M.
Polar Asset Management Partners first reported a position in ADMA Biologics in Q4 2021 and held it in 3 quarters.
Polar Asset Management Partners's ADMA Biologics position peaked at $2.36M in Q1 2022.
130 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2022.

Based on Polar Asset Management Partners's 13F filing for Q3 2022, filed 14 Nov 2022.